Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 7/20 | 0.49 |
| ▸ | RAB9A | P51151 | 7/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL539051 | 0.85 | NPC1 (0.54) | KDM4EMAPTHSD17B10NPC1RAB9A | |
| SCHEMBL30602943 | 0.85 | NPC1 (0.54) | KDM4EMAPTHSD17B10NPC1RAB9A | |
| SCHEMBL14858629 | 0.80 | ELANE (0.40) | KDM4EMAPTHSD17B10NPC1RAB9A | |
| SCHEMBL11094502 | 0.80 | ALDH1A1 (0.44) | KDM4EMAPTHSD17B10NPC1RAB9A | |
| SCHEMBL22382609 | 0.80 | ELANE (0.40) | KDM4EMAPTTDP1ELANEXDH | |
| SCHEMBL1563928 | 0.80 | ESR1 (0.53) | NPC1RAB9A | |
| SCHEMBL12384123 | 0.80 | PIK3CG (0.56) | KDM4EMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31294143 | 0.80 | KDM4E (0.50) | KDM4EMAPTHSD17B10NPC1RAB9A | |
| SCHEMBL9536038 | 0.77 | KDM4E (0.51) | KDM4EMAPTHSD17B10NPC1RAB9A | |
| SCHEMBL24133266 | 0.77 | KDM4E (0.59) | KDM4EMAPTHSD17B10NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166161-B | Compounds having PDE9A inhibiting activity and pharmaceutical uses thereof | 韩国化学研究院 | 2023-10-27 | — | — | CN | disclosed |
| US-8013166-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013166-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013166-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2011-09-06 | — | — | US | disclosed |
| EP-1633722-B1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2011-08-03 | — | — | EP | disclosed |
| US-7968576-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER A | 2011-06-28 | — | — | US | disclosed |
| US-7968576-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER A | 2011-06-28 | — | — | US | disclosed |
| US-7968576-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER A | 2011-06-28 | — | — | US | disclosed |
| US-7790893-B2 | Modified carbocyanine dyes and their conjugates | Life Technologies Corporation (US) | 2010-09-07 | — | — | US | disclosed |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER | 2009-10-29 | — | — | US | disclosed |
| EP-1633722-A2 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050176720-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC | 2005-08-11 | — | — | US | disclosed |
| US-6881734-B2 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC. (US) | 2005-04-19 | — | — | US | disclosed |
| WO-2004100881-A2 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | disclosed |
| US-6809094-B2 | N-FUSED HETERCYCLO-1,4- OR -1,5- DIAZABICYCLO DERIVATIVES; NICOTINIC RECEPTOR AGONISTS; CENTRAL NERVOUS SYSTEM (CNS) | PFIZER INC | 2004-10-26 | — | — | US | disclosed |
| US-20040204416-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC | 2004-10-14 | — | — | US | disclosed |
| US-20030119837-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC. | 2003-06-26 | — | — | US | disclosed |
| US-20020086871-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | O'NEILL BRIAN THOMAS (US) | 2002-07-04 | — | — | US | disclosed |
| EP-1219622-A2 | Pharmaceutical compositions for CNS and other disorders | Pfizer Products Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176720-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | CHRNA7, CHRNA10, CHRNA5 | KDM4E 4027/4885MAPT 185/4885HSD17B10 1550/4885 |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | KDM4E 817/4885MAPT 4379/4885HSD17B10 121/4885 |
| US-20030119837-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | CHRNA7, CHRNA5, CHRNA10 | KDM4E 4365/4885MAPT 223/4885HSD17B10 1548/4885 |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | KDM4E 817/4885MAPT 4379/4885HSD17B10 121/4885 |
| US-20020086871-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | CHRNA7, CHRNA5, CHRNA10 | KDM4E 4365/4885MAPT 223/4885HSD17B10 1548/4885 |
| US-20040204416-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | CHRNA7, CHRNA5, CHRNA10 | KDM4E 4365/4885MAPT 223/4885HSD17B10 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.